Clinical risk factors for mortality of hospitalized patients with COVID-19: systematic review and meta-analysis
- PMID: 33549005
- DOI: 10.21037/apm-20-1278
Clinical risk factors for mortality of hospitalized patients with COVID-19: systematic review and meta-analysis
Abstract
Background: New evidence from retrospective cohort studies on risk of death from COVID-19 infection became available. We aimed to systematically review the clinical risk factors for fatal outcome of COVID-19.
Methods: We performed meta-analysis, using PubMed, EMBASE and Cochrane databases from December 1 2019 to June 10 2020. The meta-analysis summarized clinical, laboratory, radiological features, and complications of non-survivors with confirmed COVID-19. In addition, a fixed- or random-effects model was adopted based on the heterogeneity among studies. We also used funnel-plot with Egger's tests to screen potential publication bias.
Results: In total, twenty studies with 15,408 COVID-19 cases were included in our meta-analysis. Male, current smoking, and older age were associated with in-hospital death. Patients aged 60 years or over had the highest pooled ORs [OR 4.94 (2.89, 8.44)]. Non-survivors were more likely to have diabetes, hypertension, cardiovascular disease (CVD), respiratory disease, or chronic kidney disease (CKD). Respiratory disease had the highest pooled ORs [OR 2.55 (2.14, 3.05)]. Dyspnea [OR 3.31 (1.78, 6.16); I2 : 83%] and fatigue [OR 1.36 (1.07, 1.73); I2 : 0%] were associated with increased risk of death. Increased white blood cell count, decreased lymphocyte and platelet counts, were also associated with increased risk of death. Biomarkers of coagulation function, inflammation, liver and kidney function, cardiac and muscle injury were also elevated in nonsurvivors.
Conclusions: Male, current smoking patients aged 60 years or over might face a greater risk of in-hospital death and the comorbidities such as diabetes, hypertension, CVD, respiratory disease, and CKD could also influence the prognosis of the COVID-19. Clinical feature such as dyspnea and fatigue could imply the exacerbation and even death. Our findings highlighted early markers of mortality which were beneficial to identify fatal COVID-19.
Keywords: COVID-19; SARS-CoV-2; mortality; risk factor.
Similar articles
-
Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients.BMC Infect Dis. 2021 Aug 21;21(1):855. doi: 10.1186/s12879-021-06536-3. BMC Infect Dis. 2021. PMID: 34418980 Free PMC article.
-
Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies.Aging Male. 2020 Dec;23(5):1416-1424. doi: 10.1080/13685538.2020.1774748. Epub 2020 Jun 8. Aging Male. 2020. PMID: 32508193
-
Risk factors for mortality in hemodialysis patients with COVID-19: a systematic review and meta-analysis.Ren Fail. 2021 Dec;43(1):1394-1407. doi: 10.1080/0886022X.2021.1986408. Ren Fail. 2021. PMID: 34629011 Free PMC article.
-
Cardiovascular risk factors and mortality in hospitalized patients with COVID-19: systematic review and meta-analysis of 45 studies and 18,300 patients.BMC Cardiovasc Disord. 2021 Jan 7;21(1):23. doi: 10.1186/s12872-020-01816-3. BMC Cardiovasc Disord. 2021. PMID: 33413093 Free PMC article.
-
Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients.PLoS One. 2020 Dec 7;15(12):e0243191. doi: 10.1371/journal.pone.0243191. eCollection 2020. PLoS One. 2020. PMID: 33284825 Free PMC article.
Cited by
-
Association between ventilatory ratio and mortality in patients with acute respiratory distress syndrome and COVID 19: A multicenter, retrospective cohort study.BMC Pulm Med. 2023 Nov 3;23(1):425. doi: 10.1186/s12890-023-02733-9. BMC Pulm Med. 2023. PMID: 37924051 Free PMC article.
-
The risk factors and related hospitalizations for cases with positive and negative COVID-19 tests: A case-control study.Int Immunopharmacol. 2021 Sep;98:107894. doi: 10.1016/j.intimp.2021.107894. Epub 2021 Jun 15. Int Immunopharmacol. 2021. PMID: 34186280 Free PMC article.
-
The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19.Drug Des Devel Ther. 2023 Jan 19;17:87-92. doi: 10.2147/DDDT.S392708. eCollection 2023. Drug Des Devel Ther. 2023. PMID: 36698540 Free PMC article. Clinical Trial.
-
Hypertension and mortality in SARS-COV-2 infection: A meta-analysis of observational studies after 2 years of pandemic.Eur J Intern Med. 2023 Feb;108:28-36. doi: 10.1016/j.ejim.2022.11.018. Epub 2022 Nov 17. Eur J Intern Med. 2023. PMID: 36411156 Free PMC article.
-
The Relationship between Ageism and Well-Being as Mediated through COVID-19-Related Experiences and Discourses.Int J Environ Res Public Health. 2021 Oct 6;18(19):10490. doi: 10.3390/ijerph181910490. Int J Environ Res Public Health. 2021. PMID: 34639790 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous